生物/靶向合成改善病情抗风湿药不能阻止类风湿关节炎患者骨量丢失:长期多中心观察研究
该多中心观察研究纳入797例接受b/tsDMARDs治疗的活动性RA患者,随访中位3.1年,评估骨密度T评分变化。结果显示,未接受抗骨质疏松治疗组股骨颈和桡骨T评分显著下降,而抗骨质疏松治疗组未显著下降;b/tsDMARD使用时长和平均CDAI与骨密度维持无关。结论提示即使RA活动被控制,骨密度仍下降,骨质疏松应作为RA独立方面管理。
要点
- b/tsDMARDs治疗期间即使RA疾病活动改善,骨密度仍可能下降。
- 未接受抗骨质疏松治疗者股骨颈和桡骨T评分显著降低。
- b/tsDMARD使用时长及平均CDAI与骨密度维持无关联。
核心结论
- 即使使用b/tsDMARDs控制RA活动,骨密度仍会下降,骨质疏松应被视为RA独立于炎症控制之外的方面。
研究设计与样本
- 多中心长期观察研究,纳入797例接受b/tsDMARDs治疗的活动性RA患者,中位随访3.1年(共2489患者年)。
主要发现
- 未接受抗骨质疏松治疗组股骨颈和桡骨T评分显著下降(平均变化-0.11至-0.33,均P<0.001)。
- 接受抗骨质疏松治疗组股骨颈和桡骨T评分无显著下降(P=0.830和P=0.071)。
- 总体460例(58%)患者出现T评分下降。
- 基线T评分较高与后续T评分下降相关,而抗骨质疏松治疗疗程较长与T评分增加相关。
- b/tsDMARD使用时长和观察期间平均CDAI与骨密度维持无关。
关键数值与推荐
- 未接受抗骨质疏松治疗组股骨颈和桡骨T评分平均变化分别为-0.11和-0.33(均P<0.001)。
- 接受抗骨质疏松治疗组股骨颈和桡骨T评分平均变化分别为-0.01和-0.10(P=0.830和P=0.071)。
- CDAI在未接受抗骨质疏松组从26.0降至6.6,在接受抗骨质疏松组从24.4降至6.8。
临床怎么用
- 对接受b/tsDMARDs治疗的RA患者,应独立评估和管理骨质疏松,不能仅依赖控制炎症来维持骨密度。
- 考虑对RA患者进行骨密度监测,并根据需要给予抗骨质疏松治疗。
局限性
- 原文未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Osteoporosis causes fractures that further increase the disease burden of rheumatoid arthritis (RA); however, osteoporosis treatment rates remain low. Although several studies have reported that biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) can prevent or improve osteoporosis in RA, our large-scale, real-world study showed that one-year b/tsDMARDs use did not arrest osteoporosis progression. This study aimed to examine longer-term changes in bone mineral density (BMD). METHODS: BMD was observed for up to five years in patients receiving b/tsDMARDs for active RA. The primary endpoint was change in BMD (T score), and the secondary endpoint was change in T score-related factors. RESULTS: In total, 797 patients (antiosteoporosis-, n = 645; antiosteoporosis+, n = 152) were included, with a median 3.1-year follow-up (2,489 patient-years). Clinical Disease Activity Index (CDAI) improved in both groups (antiosteoporosis- 26.0 to 6.6; antiosteoporosis+ 24.4 to 6.8). T scores decreased significantly in the femoral neck and radius in the antiosteoporosis- group but not in the antiosteoporosis+ group (antiosteoporosis-: mean change -0.11 to -0.33, both P < 0.001; antiosteoporosis+ -0.01 to -0.10, P = 0.830 and 0.071, respectively). Overall, 460 patients (58%) experienced a decrease in T score. A high baseline T score correlated with a subsequent decrease, whereas longer osteoporosis treatment duration correlated with an increase. Unexpectedly, the duration of b/tsDMARD use and mean CDAI during observation were not associated with BMD maintenance. CONCLUSION: Even when RA activity was controlled with b/tsDMARDs, BMD still decreased. This study emphasizes the importance of considering osteoporosis as an independent aspect of RA, beyond inflammation control.
引用
- Aritomi T, Sonomoto K, Nakayamada S, et al. Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs Do Not Arrest Bone Loss in Patients With Rheumatoid Arthritis: A Long-Term Multicenter Observational Study. Arthritis Rheumatol. 2026. PMID: 41797301. doi:10.1002/art.70125
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。